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Abstract
Blood culture-negative endocarditis is often severe and difficult to diagnose. Infective 
blood culture-negative endocarditis is classified into three main categories: (1) bacte-
rial endocarditis with blood cultures sterilized by previous antibacterial treatment; 
(2) endocarditis related to fastidious microorganisms in which prolonged incubation 
is necessary; (3) true blood culture-negative endocarditis, due to intra-cellular bacte-
ria that cannot be routinely cultured in blood with currently available. There are two 
major etiologies for noninfective endocarditis: (1) nonbacterial thrombotic endocar-
ditis and (2) endocarditis related to systemic diseases (SLE and Behcet disease). Team 
approach including cardiologists, infection disease (ID) specialists, microbiologists, 
pathologist and immunologist is crucial for diagnosis and management of blood cul-
ture-negative endocarditis as it needs elegant and high-quality modern technics of 
histology, molecular analysis and essential epidemiological information.
Keywords: blood culture-negative endocarditis, fastidious microorganisms,  
intra-cellular bacteria, noninfective endocarditis
1. Introduction
Blood culture-negative IE (BCNIE) refers to infective endocarditis (IE) in which no causative 
microorganism can be grown using the usual blood culture methods. BCNIE accounts for 
5–10% of all cases of endocarditis [1]. This variation is caused by differences in the diagnostic 
criteria and sampling strategies used. A European study included 820 cases indicated 20% of 
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patients with confirmed IE had negative blood cultures [2]. BCNIE often produces considerable 
diagnostic and therapeutic dilemmas, which result in poor prognosis.
2. Main etiologies of BCNIE
There are three main causes for BCNIE.
1. Administration to antimicrobial agents before blood culture.
2. Endocarditis related to fastidious microorganisms in which prolonged incubation is 
necessary.
3. True blood culture-negative endocarditis, due to intra-cellular bacteria that cannot be de-
tected by currently available routine blood culture system.
If all microbiological assays are negative, noninfective endocarditis is considered, and sys-
tematically differential diagnosis should be performed. Nonbacterial thrombotic endocarditis 
(marantic endocarditis) in patients with malignant tumor and systemic diseases such as SLE 
and Behҫet are two main causes of noninfective endocarditis.
3. Diagnostic approach
Definitions of the terms used in the European Society of Cardiology 2015 [4] modified criteria 
adapted from modified Duke Criteria [3] were shown in Table 1. Diagnosis of IE is drawn as 
follows:
3.1. Definition
Pathological criteria: Microorganisms demonstrated by culture or on histological examina-
tion of a vegetation, a vegetation that has embolized, or an intracardiac abscess specimen; or 
pathological lesions; vegetation or intracardiac abscess by histological examination showing 
active endocarditis.
Clinical criteria: two major criteria; or one major criterion and three minor criteria or five minor 
criteria.
Possible IE: One major criterion and one minor criterion or three minor criteria.
Rejected IE: Firm alternate diagnosis; or Resolution of symptoms suggesting IE with antibiotic 
therapy for ≤4 days; or No pathological evidence of IE at surgery or autopsy, with antibiotic 
therapy for ≤4 days; or Does not meet criteria for possible IE, as above.
When blood culture is negative, systematic diagnostic approach should be performed for 
rapid and correct management of BCNIE. Diagnostic work-up in blood culture-negative 
endocarditis is shown in Figure 1 [1, 4].
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3.2. Past history and clinical examination
A precise interview about epidemiological factors, history of prior infections, exposure to 
antimicrobials, should be made in all patients with suspected BCNIE [1, 4].
Previous exposure to antibiotics is the most common cause of BCNE, and even a short course 
of antibiotics can cause long-lasting suppression of bacterial activity. A history of animal 
exposures may predispose to certain microbiologic etiologies. Immunosuppression or pro-
longed antibiotic therapy suggests endocarditis due to fungi. The epidemiological clues for 
defining the etiology of BCNIE are shown in Table 2 [1].
Major criteria
1.  Blood cultures positive for IE
a. Typical microorganisms consistent with IE from two separate blood cultures
*Streptococcus viridance, Streptococcus bovis, HACEK group, Staphylococcus aureus
*Community-acquired enterococci, in the absence of a primary focus
b. Microorganisms consistent with IE from persistently positive blood cultures defined as follows
*>2 positive blood cultures of blood samples drawn >12 h part; or
*All of 3 or a majority of >4 separate cultures of blood (with first and last samples (drawn>1 h apart)
c. Single positive blood culture for Coxiella burnetii or phase I IgG antibody titer>1:800
2.  Imaging positive for IE
a. Echocardiogram positive for IE: vegetation, abcess, pseudoaneurysm, intracardiac fistula, valvular perforation 
or aneurysma, new partial dehiscence of prosthetic valve
b. Abnormal activity around the site of prosthetic valve implantation detected by 18F-FDG PET/CT (only if the 
prosthesis was implanted for 3 months) or radiolabeled leukocytes SPECT/CT.
c. Definite paravalvular lesion by cardiac CT.
Minor criteria
1.  Predisposition such as predisposing heart condition, or injection drug use.
2.  Fever defined as temperature > 38°C
3.  Valvular phenomena (including those detected by imaging only) major arterial emboli, septic pulmonary infarcts, 
infectious (mycotic) aneurysm, intracranial hemorrhages, conjunctival hemorrhages and Janeway’s lesions.
4.  Microbiological evidence: positive blood culture but does not meet a major criterion as noted above or serological 
evidence of active infection with organism consistent with IE
CT, computed tomography; FDG, fluorodeoxyglucose; HACEK, Haemophilus parainfluenzae, H. aphrophilus, 
H. paraphrophilus, H. influenzae, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella 
corrodens, Kingella kingae, and K. denitrificans; IE, infective endocarditis; Ig, immunoglobulin; PET, positron emission 
tomography; SPECT, single photon emission computerized tomography.
Table 1. Definitions of the terms used in the European Society of Cardiology 2015 modified criteria adapted from modified 
Duke criteria.
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3.3. Blood culture
BCNIE occurs frequently (45–60%) by common and easily grown staphylococci or streptococci 
in patients with preceding administration of antibiotics as it reduces the recovery rate of bac-
teria by 35–40% [5, 6]. In these cases, withdrawing antibiotics and repeating blood cultures are 
preferable methods to diagnose if the patient status allowed. The use of specific blood culture 
bottles for fastidious microorganisms is not recommended recently [1, 4, 5]. The extended 
incubation is applied only when cultures remain sterile after 48–72 h. Sophisticated auto-
mated systems allow isolating most pathogens that can grow slowly including Candida sp., 
deficient streptococci and HACEK group bacteria(Haemophilus, Aggregatibacter (previously 
Figure 1. Diagnostic workup in blood culture-negative endocarditis.
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Actinobacillus), Cardiobacterium, Eikenella, Kingella). Extending culture beyond 5 days is not 
contributive [1, 4–8]. The popular pathogens such as staphylococci, streptococci and entero-
cocci are usually identified within 48 h. The European guidelines recommend that clinicians 
require prolonged incubation of vials only in the rare cases of cultures remaining negative at 
48–72 h and if the diagnosis of IE remains plausible [4, 8].
3.4. Serology
The list of serological tests to be performed in case of blood culture-negative endocarditis used 
to include: Legionella pneumophila, Mycoplasma hominis, Chlamydophila pneumoniae, Brucella sp., 
Coxiella burnetii (C. burnetii), and Bartonella sp. Two major series showed that only Bartonella sp. 
and C. burnetii serological tests are contributive: 348 cases of suspected BCNIE were investigated 
between 1983 and 2001, the diagnosis was documented by serological tests in 268 cases (77%), 
Epidemiological feature Suspected microorganisms
Alcoholism, Cirrhosis Bartonella sp., Aeromnas sp., Listeria sp.
Burn S. aureus, Aerobic Gram-negative bacilli, Fungi
Chronic skin disorders S. aureus, β-hemolytic streptococci
Genitourinary disorders Enterococcus, GroupB streptococci, aerobic Gram-negative bacilli, Neisseria 
gonorrhoeae, Listeria monocytoogenes
Intravenous drug use, cardiovascular 
medical devices
S. aureus, CNS, Aerobic Gram-negative bacilli, β-Hemolytic streptococci, 
Fungi
Prosthetic valve replacement Early(<1y): CNS, S. aureus, Aerobic Gram-negative bacilli, Fungi, 
Corynebacterium sp., Legionella sp., Late(>1y): CNS, S. aureus, Viridance 
Streptcoccus sp., Enterococcus sp., Fungi, Corynebacterium
Exposure to dog and/or cat Bartonella sp.,Pasteurella sp.
Contact with contaminated milk or farm 
animal
Brucella sp., Cociella bumetii
Homeless, body lice Bartonella sp.
Gastrointestinal lesions S. gallolytics (bovis), Enterococcus sp., Clostridium spectrum
Dog or cat exposure Bartonella sp., Pasteurella sp., Capnocytophaga sp.
Homeless, body lice Bartonella sp.
Contact with contaminated milk or 
infected farm animals
Brucella sp., Coxiella bumetii, Erysipelothrix sp.
Diabetes mellitus S. aureus, β-Hemolytic streptococci, S. pneumoniae
AIDS Salmonella sp., S. pneumoniae, S. aureus
Organ transplantation S. aureus, Aspergillus fumigatus, Enterococcus sp., Candida sp.
Table 2. Epidemiological clues for defining the etiology of blood culture-negative infective endocarditis S. aureus, 
Staphylococcus aureus; CNS, coagulase -negative staphylococci; S. gallolytics, Streptococcus gallolyticus; Streptococcus 
pneumonie.
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Pathogen Diagnostic procedures
Brucella sp. blood cultures, serology, immunohistology, PCR of surgical materials
Coxiella burnetii serology (IgG phaseI >1:800, tissue culture, immunohistology, PCR of surgical 
materials
Bartonella sp. blood cultures, serology, culture, immunohistology, PCR of surgical materials
Tropheryma whippplei hystology and PCR of surgical materials
Mycoplasma sp. serology, culture, immunohistology, PCR of surgical materials
Legionella sp. blood cultures, serology, culture, immunohistology, PCR of surgical materials
Fungi blood cultures, serology, immunohistology, PCR of surgical materials
Table 3. Summary of diagnostic procedure of rare pathogens of blood culture-negative infective endocarditis.
including 266 cases of C. burnetii (n = 167) or Bartonella sp. (n = 99) [5]. The same team reported 
a second series of 745 patients presenting with suspected BCNIE having received a panel of 
serological tests between 2001 and 2009. They documented the predominance of Q fever and 
Bartonellosis. A total of 354 of the 356 cases documented by serological tests were positive 
for C. burnetii (n = 274) or Bartonella sp. (n = 80) [6]. In other words, if only Bartonella sp. and 
C. burnetii serological tests had been used, only 4 out of 624 diagnoses obtained by serologi-
cal tests would have been missed. A review of endocarditis caused by fastidious pathogens 
shows that Mycoplasma sp. endocarditis is very rare (<10 reliable observations published to 
date, mostly due to M. hominis), as well as Legionella sp. endocarditis [7]. Moreover, most 
cases of endocarditis supposedly due to Chlamydophila sp. are probably cross-reactions with 
a Bartonella sp. In 2015, the only routinely recommended serological tests in case of negative 
blood cultures are tests for Q fever and Bartonellosis [4]. Brucellosis serological tests can be 
added in case of risk factors (living in endemic areas, occupational exposure, consumption of 
nonpasteurized dairy products). Serological tests for Mycoplasma sp. and Legionella sp. are 
still recommended in the 2015 ESC guidelines [4].
3.5. Evaluation of valve tissue
The more frequent use of valve replacement in the acute phase of infective endocarditis and 
the advent of molecular biology techniques have revolutionized the diagnosis of blood cul-
ture-negative endocarditis:
PCR systems based on universal bacterial 16S ribosomal RNA have demonstrated excellent 
sensitivity and specificity [8, 9], as well as PCR targeting bacteria specifically responsible for 
endocarditis with negative blood culture: Bartonella sp., C. burnetii [10] and Tropheryma whipplei 
(T. whipplei) [11].
Moreover, the microscopic examination of valves after Gram staining, and cultures on appropri-
ate media provide important information not only for the identification of the pathogen involved 
when the data were not available preoperatively [12], but also information on its viability at the 
time of valve replacement, which will impact the duration of post-replacement treatment [11, 13]. 
The histological analysis of valves is not contributive to diagnose except some rare diagnoses 
such as porcine bioprosthesis endocarditis mediated by allergy to porcine proteins [22, 23]. 
Summary of diagnostic procedure of rare pathogens of BCNIE is shown in Table 3.
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4. Treatment
4.1. Empirical therapy
Selection of medical therapy for patients with BCNIE is difficult. Some of the laboratory-
based diagnostic techniques to define fastidious or rare pathogens are not available in most 
clinical laboratories. It consumed considerable time for completion of testing if specimens are 
sent to a referral laboratory. Patients with BCNIE are often treated empirically for the more 
common bacterial causes of IE during the waiting time. There is a need to provide empiri-
cal antimicrobials for all likely pathogens, though certain therapeutic agents, including ami-
noglycosides, have potentially toxic effects. Consultation with an ID specialist to define the 
most appropriate choice of therapy is recommended. Once additional clinical and laboratory 
data were brought, initial empirical therapy should be changed to more specific treatment. 
For patients with acute (days) clinical presentations of native valve infection, coverage for S 
aureus, β-hemolytic streptococci, and aerobic Gram-negative bacilli is reasonable. Empirical 
coverage could include vancomycin and cefepime as an initial regimen [1, 4, 14]. For patients 
with a subacute (weeks) presentation of native valve IE, empirical coverage of S. aureus, 
Viridance group streptococci (VGS), HACEK, and enterococci is reasonable. One treatment 
option could include vancomycin and ampicillin-sulbactam to provide some coverage for 
these organisms [1, 4, 14]. For patients with culture-negative prosthetic valve IE, coverage 
for staphylococci, enterococci, and aerobic Gram-negative bacilli is reasonable if the onset of 
symptoms is within 1 year of prosthetic valve placement. A regimen could include vancomy-
cin, rifampin, gentamicin [1, 4, 14]. If symptom onset is >1 year after valve placement, then IE 
is more likely to be caused by staphylococci, VGS, and enterococci, and antibiotic therapy for 
these potential pathogens is reasonable [1, 4, 14]. One initial treatment option could include 
vancomycin and ceftriaxone. If subsequent blood culture results or other laboratory method-
ologies define a pathogen, then empirical therapy should be changed to focused therapy that 
is recommended for the specific pathogen identified.
4.2. Antibiotic treatment for fastidious microorganisms
HACEK Gram-negative bacilli are fastidious organisms, and the laboratory should be made 
aware that infection with these agents needs consultation to specialist. Because of slow growth, 
standard MIC tests may be difficult to interpret. Some HACEK-group bacilli produce beta-
lactamases, and ampicillin is therefore no longer the first-line option. They are susceptible to 
ceftriaxone, other third-generation cephalosporins and quinolones; the standard treatment 
is ceftriaxone 2 g/day for 4 weeks in native valve endocarditis and for 6 weeks in prosthetic 
valve endocarditis. If they do not produce beta-lactamase, ampicillin (12 g/day i.v. in four 
or six doses) plus gentamicin (3 mg/kg/day) divided into two or three doses for 4–6 weeks 
is an option [1, 4, 13]. Ciprofloxacin (400 mg/8–12 h i.v. or 750 mg/12 h orally) is a less well-
validated alternative. Clinical outcome of HACEK endocarditis is favorable.
In cases with fungi, mortality is very high, and treatment necessitates combined antifungal 
administration and surgical valve replacement. Antifungal therapy for Candida sp. includes 
liposomal amphotericin B with or without flucytosine or an echinocandin at high doses; and for 
Aspergillus spp., voriconazole is the drug of choice and some experts recommend the addition 
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of an echinocandin or amphotericin B. Suppressive long-term treatment with oral azoles (fluco-
nazole for Candida and voriconazole for Aspergillus) is recommended [1, 4, 14]. Consultation 
with an infectious doctor specialist in the Endocarditis Team is recommended.
4.3. Specific therapy for true culture-negative microorganisms
The recommended therapy for true culture-negative microorganisms in the European guide-
lines 2015 is shown in Table 4 [4, 12]. Consultation with ID specialist is highly recommended 
for the treatment of these special organisms. This is an area with a very limited level of evi-
dence. The treatment of T. whipplei endocarditis has not been standardized. Doxycycline + 
hydroxychloroquine for 12–18 months, with monitoring of plasma levels of these two 
agents (objective: achieving plasma concentrations of 0.8–1.2 mg/L for hydroxychloroquine, 
and < 5 mg/L for doxycycline), and of negativation of samples initially positive for T. whipplei 
was proposed. The treatment of Bartonella sp. endocarditis is a beta-lactam antibiotic (amoxi-
cillin or ceftriaxone) or doxycycline for 4 weeks in combination with gentamicin for the first 
2 weeks [1, 4, 14] the treatment of C. burnetii endocarditis, is doxycycline + hydroxychloro-
quine until a phase1 antibody rate <800 is reached for IgG, and <50 for IgM and IgA [1, 4, 14].
4.4. Surgical treatment of blood culture-negative IE
There is no specific recommendation for surgical treatment of BCNIE: cardiac surgery indica-
tions rely on the same criteria that apply for any type of endocarditis (heart failure, uncon-
trolled infection, risk of embolism [1, 4, 15]). However, an additional argument for the surgical 
treatment of BCNIE is the ability to harvest valve tissue, which often finally allows microbio-
logical documentation.
Pathogens Standard therapy Treatment outcome
Brucella sp. Doxycycline (200 mg/day)
+ contrimocazole (960 mg/12 h)
+ rifampicine (300~600 mg/day
for ≥3~6 months orally
Treatment success defined 
as IgG < 1:60
Bartonella sp. Doxycycline (100 mg/12 h) orally for 4 weeks
+ gentamicin (3 mg/day) iv for 2 weeks
Success rate > 90%
Coxiella.burnetii
(Q fever)
Doxycycline (200 mg/day) + hydroxychloroquine  
(200–600 mg/day) orally for ≥18 months
Treatment success defined 
as phase I IgG < 1:200
IgM, IgA < 1:50
Legionella sp. Levofloxacin (500 mg/12 h) iv or orally for ≥6 weeks or 
clarithromycin (500 mg/12 h) iv for 2 weeks, then orally for 
4 weeks + rifampin (300–1200 mg/24 h)
Optimal treatment
unknown
Mycoplasma sp. Levofloxacin (500 mg/12 h) iv or orally for ≥6 weeks Optimal treatment
unknown
Treaponema whipplei
(Whipple’s disease)
Doxycycline (200 mg/day) + hydroxychloroquine 
(200–600 mg/day) orally for ≥18 months
Long-term treatment,
optical duration unknown
Table 4. Recommended therapy for true culture-negative microorganisms in the European guidelines 2015.
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5. Noninfective endocarditis
When all microbiological assays are negative, the diagnosis of noninfectious endocarditis 
should systematically be considered (Figure 1).
5.1. Nonbacterial thrombotic endocarditis
Nonbacterial thrombotic endocarditis (marantic endocarditis, Trousseau syndrome) is 
observed in 1.2% of patients with active cancer at autopsy [16]. Usually, the single or multiple 
small vegetation-like lesions are observed predominantly on the mitral and aortic valves with 
no underlying valve diseases. These are associated with an underlying hypercoagulable state 
that justifies routine anticoagulation. Control of pathologically altered coagulation mecha-
nism is essential for the treatment and the prognosis is poor without resolving the problem. 
The differential diagnosis with an infectious cause of BCNIE is often difficult, and the prog-
nosis is poor [17]. The initial lesion is usually breast, lung, prostate, ovarian or colon cancer. 
However, it should not be forgotten that undiagnosed infective endocarditis is also common 
in cancer patients with sterile blood cultures and/or fastidious organisms that are difficult to 
identify by conventional methods.
5.2. Systemic diseases
Inflammatory diseases can cause endocarditis and produce a syndrome similar to culture-
negative IE. Perhaps the one most often encounter is antiphospholipid antibody (APA) 
syndrome [18], which has been described as both a primary and a secondary syndrome of 
systemic lupus erythematosus(SLE) and malignancies. Sterile valvular vegetations form and 
often embolize, clinically mimicking in many respects with IE. The mitral valve is most often 
affected, and valvular regurgitation is the frequent functional abnormality. To complicate 
matters, the APA syndrome may also develop secondary to IE [19].
In patients with SLE, valve abnormalities are common (15–75% of autopsy series, depending on 
the severity of the disease), but rarely progress to a clinical stage of Libman-Sacks endocarditis 
[20]. The patients are usually young individuals with a very severe lupus poorly controlled by 
treatments. Immunological manifestations (Osler nodes) and embolism (stroke, often in combi-
nation with an antiphospholipid syndrome) may be observed. Valve lesions are mainly found 
in the left heart. Endocardium involvement may occur in Behҫet’s disease [21]. It is a disease of 
young ± male patients with a predominantly aortic involvement. Endocardium involvement in 
Behҫet’s disease is a poor prognostic factor. The treatment is of course should be targeted on the 
systemic disease (immune-suppressants, immune-modulators) with lifelong curative anticoag-
ulation. Checkup for antinuclear antibodies as well as antiphospholipid antibody {anticardio-
lipin antibodies [immunoglobulin (Ig) G and anti-b2-glycoprotein 1 antibodies [IgG and IgM]} 
should be performed for the patients who are suspected to have noninfective endocarditis.
5.3. Allergy for porcine valve
When the patient has a porcine bioprosthesis implanted during last 6 months, anti-pork anti-
bodies should be sought [22, 23] to consider allergy for the valve.
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6. Conclusion
Blood culture-negative endocarditis is still a clinical challenge with heterogeneous pathology. 
Remarkable progress has been made in methodologies to evaluate the main etiologies in past 
two decades. Team approach including cardiologists, infectious disease specialists, microbi-
ologists and immunologist is crucial for the correct diagnosis that is able to reach rapidly the 
new diagnostic microbiological techniques, and high-quality epidemiological information.
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